Dyne Therapeutics, Inc. DYN Financing Cash Flow
Financing Cash Flow at other companies
Other financials
Where this comes from
Reported directly by Dyne Therapeutics, Inc. in its filing.
Tagged under the XBRL concept us-gaap:NetCashProvidedByUsedInFinancingActivities.
The official record: Dyne Therapeutics, Inc.’s 10-Q, filed May 11, 2026, on SEC EDGAR. View the filing →
Ask your AI about Dyne Therapeutics, Inc.'s financing cash flow.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Dyne Therapeutics, Inc.'s financing cash flow?
- Dyne Therapeutics, Inc. (DYN) reported financing cash flow of $7.06M in Q1 2026.
- How has Dyne Therapeutics, Inc.'s financing cash flow changed year-over-year?
- Dyne Therapeutics, Inc.'s financing cash flow decreased by 95.0% year-over-year, from $141.24M to $7.06M.
- What is the long-term trend for Dyne Therapeutics, Inc.'s financing cash flow?
- Over 4 years (2021 to 2025), Dyne Therapeutics, Inc.'s financing cash flow has grown at a 54.1% compound annual growth rate (CAGR), from $157.82M to $890.31M.
- What does financing cash flow mean?
- Total net cash provided by or used in financing activities — debt issuance/repayment, equity transactions, and dividend payments.